

Diana A Gorog

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6838803/diana-a-gorog-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

102
papers

1,497
citations

22
h-index

35
g-index

118
ext. papers

2,145
ext. citations

5.3
avg, IF

5.37
L-index

#	Paper	IF	Citations
102	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium.. <i>Nature Reviews Cardiology</i> , 2022 ,	14.8	16
101	Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock: JACC Review Topic of the Week.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1949-1962	15.1	1
100	Global Thrombosis Test: Occlusion Is Attributable to Shear-Induced Platelet Thrombus Formation.. <i>TH Open</i> , 2021 , 5, e591-e597	2.7	
99	Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute Cardiovascular Care and the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 343-355	4.3	4
98	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. <i>Cardiology Journal</i> , 2021 ,	1.4	1
97	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis. <i>American Journal of Cardiology</i> , 2021 , 142, 147-151	3	4
96	Assessment of endogenous fibrinolysis in clinical practice using novel tests: ready for clinical roll-out?. <i>SN Applied Sciences</i> , 2021 , 3, 1	1.8	
95	Out-of-hospital cardiac arrest: A systematic review of current risk scores to predict survival. <i>American Heart Journal</i> , 2021 , 234, 31-41	4.9	2
94	Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Committee on Practice Guidelines. <i>European Heart Journal</i> , 2021 , 42, 2215-2219	9.5	22
93	Incidence of thrombotic complications in COVID-19 : On behalf of ICODE: The International COVID-19 Thrombosis Biomarkers Colloquium. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 999-1006	5.1	11
92	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2021 , 42, 4638-4651	9.5	21
91	Screening for venous thromboembolism in patients with COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 985-991	5.1	4
90	RIC in COVID-19-a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	0
89	Spontaneous Reperfusion in Patients with Transient ST-Elevation Myocardial Infarction-Prevalence, Importance and Approaches to Management. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	1
88	When a meta-analysis equals a single large-scale trial with meaningful follow-up. <i>European Heart Journal</i> , 2021 , 42, 3884-3885	9.5	2
87	Effect of remote ischaemic conditioning on platelet reactivity and endogenous fibrinolysis in ST-elevation myocardial infarction: a substudy of the CONDI-2/ERIC-PPCI randomized controlled trial. <i>Cardiovascular Research</i> , 2021 , 117, 623-634	9.9	7
86	Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 1-11	5.1	8

85	Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 125-141	6.4	16
84	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2021, 121, 422-432	7	47
83	Endogenous fibrinolysis-Relevance to clinical thrombosis risk assessment. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13471	4.6	2
82	2-Oxothiazolidine-4-carboxylic acid inhibits vascular calcification via induction of glutathione synthesis. <i>Journal of Cellular Physiology</i> , 2021, 236, 2696-2705	7	2
81	Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences. <i>Korean Circulation Journal</i> , 2021, 51, 202-221	2.2	5
80	Prevalence of Thrombotic Complications in ICU-Treated Patients With Coronavirus Disease 2019 Detected With Systematic CT Scanning. <i>Critical Care Medicine</i> , 2021, 49, 804-815	1.4	15
79	Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 595-607	5.1	32
78	Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis. <i>International Journal of Molecular Sciences</i> , 2021, 22,	6.3	5
77	Antithrombotic therapy in diabetes: which, when, and for how long?. <i>European Heart Journal</i> , 2021, 42, 2235-2259	9.5	8
76	Preoperative Atrial Fibrillation is associated with long-term mortality in patients undergoing surgical Aortic valve Replacement. <i>Journal of Cardiac Surgery</i> , 2021, 36, 3561-3566	1.3	2
75	A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. <i>Cardiology Journal</i> , 2021, 28, 607-614	1.4	2
74	The authors reply. <i>Critical Care Medicine</i> , 2021, 49, e1190-e1191	1.4	2
73	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. <i>International Journal of Cardiology</i> , 2021, 337, 1-8	3.2	2
72	Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute Cardiovascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). <i>Cardiovascular Research</i> , 2021,	9.9	16
71	Development of a novel risk score to predict mortality in patients admitted to hospital with COVID-19. <i>Scientific Reports</i> , 2020, 10, 21379	4.9	21
70	Angiotensin Converting Enzyme 2 May Mediate Disease Severity In COVID-19. <i>American Journal of Cardiology</i> , 2020, 130, 161-162	3	6
69	Fatal heart block from intentional yew tree () ingestion: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-4	0.9	4
68	Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9,	5.1	1

67	Usefulness of the NULL-PLEASE Score to Predict Survival in Out-of-Hospital Cardiac Arrest. <i>American Journal of Medicine</i> , 2020 , 133, 1328-1335	2.4	3
66	Platelet Inhibition in Acute Coronary Syndrome and Percutaneous Coronary Intervention: Insights from the Past and Present. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 565-578	7	12
65	Impact of Preadmission Morphine on Reinfarction in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention: A Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 54-62	6.1	7
64	MI with Non-obstructive Coronary Artery Presenting with STEMI: A Review of Incidence, Aetiology, Assessment and Treatment. <i>European Cardiology Review</i> , 2020 , 15, e20	3.9	8
63	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <i>Cardiology Journal</i> , 2020 , 27, 661-676	1.4	4
62	Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 19, 100-103	5.1	2
61	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020 , 41, 3132-3140	9.5	24
60	Thrombosis Risk with Transcatheter Aortic Valve Replacement. <i>Structural Heart</i> , 2020 , 4, 349-359	0.6	
59	Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19. <i>European Heart Journal</i> , 2020 , 41, 3198-3199	9.5	14
58	Endovascular thrombectomy 2020: open issues. <i>European Heart Journal Supplements</i> , 2020 , 22, M13-M18	1.5	1
57	Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. <i>European Heart Journal Supplements</i> , 2020 , 22, M26-M34	1.5	1
56	Understanding the Effects of NOAC Combined with Antiplatelet Therapy on Clot Kinetics. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 8-10	7	
55	Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. <i>Lancet, The</i> , 2019 , 394, 1415-1424	10.2	125
54	Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation. <i>Europace</i> , 2019 , 21, 1297-1306	3.9	9
53	Impaired Spontaneous/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor?: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1366-1375	15.1	9
52	Relationship of Platelet Reactivity and Inflammatory Markers to Recurrent Adverse Events in Patients with ST-Elevation Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1785-1794	7	6
51	Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 788-796	4.9	4
50	A case of repetitive myocardial infarction with unobstructed coronaries due to Churg-Strauss syndrome. <i>European Heart Journal - Case Reports</i> , 2019 , 3,	0.9	4

49	Impaired endogenous fibrinolysis at high shear using a point-of-care test in STEMI is associated with alterations in clot architecture. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 392-395	5.1	3
48	Thrombotic Profile and Oral Anticoagulation in Asian and Non-Asian Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2822-2824	15.1	3
47	Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study. <i>European Heart Journal</i> , 2019 , 40, 295-305	9.5	32
46	Effect of P2Y inhibitors on thrombus stability and endogenous fibrinolysis. <i>Thrombosis Research</i> , 2019 , 173, 102-108	8.2	8
45	Morphine Analgesia Pre-PPCI Is Associated with Prothrombotic State, Reduced Spontaneous Reperfusion and Greater Infarct Size. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 601-612	7	28
44	More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	5
43	Potential of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 593-602	5.1	4
42	Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. <i>Vascular Health and Risk Management</i> , 2018 , 14, 13-21	4.4	11
41	Should STEMI Patients Receive Opiate Analgesia? The Morphine Paradox. <i>Current Vascular Pharmacology</i> , 2018 , 16, 477-483	3.3	7
40	Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?. <i>Current Vascular Pharmacology</i> , 2018 , 16, 427-436	3.3	0
39	METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in Patients with Unstable Angina Pectoris-The METAMORPHOSIS Trial. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 2126-2133	7	28
38	A rare cause of myocardial infarction with non-obstructive coronary arteries-case report of ST-segment elevation myocardial infarction caused by a mediastinal mass. <i>European Heart Journal - Case Reports</i> , 2018 , 2, yty008	0.9	2
37	Nitrates for the Management of Acute Heart Failure Syndromes, A Systematic Review. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017 , 22, 20-27	2.6	3
36	Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 221-234	6.4	29
35	Allopurinol as a therapeutic option in cardiovascular disease. <i>Pharmacology & Therapeutics</i> , 2017 , 172, 139-150	13.9	55
34	Percutaneous coronary intervention with drug-eluting stent versus coronary artery bypass grafting: A meta-analysis of patients with left main coronary artery disease. <i>International Journal of Cardiology</i> , 2017 , 249, 101-106	3.2	1
33	Catheter ablation for AF improves global thrombotic profile and enhances fibrinolysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 413-426	5.1	5
32	Arterial Thrombus Stability: Does It Matter and Can We Detect It?. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2036-2047	15.1	29

31	Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 457-470	7	14
30	"Mind the gap" acute coronary syndrome in women: A contemporary review of current clinical evidence. <i>International Journal of Cardiology</i> , 2017 , 227, 840-849	3.2	12
29	Importance of Endogenous Fibrinolysis in Platelet Thrombus Formation. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	10
28	98 Assessment of Endogenous Thrombolysis Predicts Cardiovascular Risk in Patient with ST-elevation Myocardial Infarction. <i>Heart</i> , 2016 , 102, A69-A70	5.1	1
27	Treatment of calcified coronary artery lesions. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 683-902.	5	8
26	Spontaneous Coronary Artery Dissection: The Phantom Menace. <i>Cardiology Research</i> , 2016 , 7, 214-217	1.8	1
25	Use of bioresorbable vascular scaffold: a meta-analysis of patients with coronary artery disease. <i>Open Heart</i> , 2016 , 3, e000462	3	5
24	Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation. <i>Platelets</i> , 2016 , 27, 687-693	3.6	12
23	Endogenous Fibrinolysis: An Important Mediator of Thrombus Formation and Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1683-1699	15.1	66
22	Global Thrombosis Test - a possible monitoring system for the effects and safety of dabigatran. <i>Thrombosis Journal</i> , 2015 , 13, 39	5.6	12
21	Usefulness of platelet function tests to predict bleeding with antithrombotic medications. <i>Cardiology in Review</i> , 2015 , 23, 323-7	3.2	5
20	Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 3801-9	4.4	2
19	Platelet function tests: why they fail to guide personalized antithrombotic medication. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	20
18	Rivaroxaban safe alternative to warfarin in atrial fibrillation cardioversion. <i>British Journal of Cardiac Nursing</i> , 2015 , 10, 41-43	0.2	
17	Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes. <i>Open Heart</i> , 2015 , 2, e000258	3	9
16	PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 38, 423-9	5.1	17
15	Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential. <i>Thrombosis Research</i> , 2014 , 133, 919-26	8.2	31
14	NOAC in acute coronary syndrome and AF?. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2014 , 14, 154-64	1.1	2

13	Platelet function tests in clinical cardiology: unfulfilled expectations. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 2115-29	15.1	61
12	Use of thrombectomy devices in primary percutaneous coronary intervention: a systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2013 , 163, 229-241	3.2	46
11	Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. <i>European Heart Journal</i> , 2013 , 34, 354-63	9.5	31
10	Novel antithrombotic agents for atrial fibrillation. <i>Pharmacology & Therapeutics</i> , 2012 , 134, 345-54	13.9	3
9	First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to the "Japanese paradox". <i>International Journal of Cardiology</i> , 2011 , 152, 43-8	3.2	40
8	Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2701-9	15.1	89
7	Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2107-15	15.1	58
6	Antiplatelet drug Resistance Part 2: laboratory resistance to antiplatelet drugs-fact or artifact?. <i>Nature Reviews Cardiology</i> , 2009 , 6, 365-73	14.8	48
5	Antiplatelet drug Resistance Part 1: mechanisms and clinical measurements. <i>Nature Reviews Cardiology</i> , 2009 , 6, 273-82	14.8	73
4	Coronary thrombosis: In vivo, ex vivo and in vitro. <i>BMJ Case Reports</i> , 2009 , 2009,	0.9	1
3	The role of distal myocardial protection devices during percutaneous coronary interventions. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007 , 9, 52-9	2.1	3
2	Distal myocardial protection during percutaneous coronary intervention: when and where?. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1434-45	15.1	31
1	A cautionary tale: the risks of flecainide treatment for myotonic dystrophy. <i>Journal of Clinical Neuromuscular Disease</i> , 2005 , 7, 25-8	1.1	2